Advertisement

Journal of Biosciences

, 44:102 | Cite as

miR-425-5p suppresses tumorigenesis and DDP resistance in human-prostate cancer by targeting GSK3β and inactivating the Wnt/β-catenin signaling pathway

  • Sheng Liu
  • Qin Wang
  • Yin Liu
  • Zong-Yu XiaEmail author
Review
  • 6 Downloads

Abstract

Prostate cancer (PCa) represents the most frequently diagnosed cancer in men. Cisplatin, also known as cis-diamminedichloroplatinum (DDP), is a standard chemotherapeutic agent used to treat PCa, and DDP resistance remains one important obstacle in DDP-based chemotherapy. In our research, we found miR-425-5p was down-regulated in PCa and even lower in DDP-resistant PCa determined by quantitative polymerase chain reaction; in contrast, GSK3β mRNA expression was upregulated in PCa and even higher in DDP-resistant PCa. Moreover, there was a modest but significant inverse correlation between the expression of GSK3β mRNA and miR-425-5p. Functional experiments showed that miR-425-5p mimic inhibited DDP resistance as evidenced by a promoted apoptosis rate (flow cytometry) and suppressed cell viability (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay) and expressions of MDR1 and MRP1 (western blotting) in DU145/DDP and PC3/DDP cells. Luciferase reporter assay and RNA immunoprecipitation identified GSK3β was a potential target of miR-425-5p. The effect of miR-425-5p mimic on DDP resistance was partially reversed by pcDNA-GSK3β. Mechanically, miR-425-5p mimic reduced expression of β-catenin, cyclin D1 and C-myc, which was further blocked when GSK3β overexpressed. In vivo experiments, recovery of GSK3β prevented xenograft tumor growth and DDP resistance in the presence of miR-425-5p mimic. To sum up, miR-425-5p upregulation might sensitize human PCa to DDP by targeting GSK3β and inactivating the Wnt/β-catenin signaling pathway.

Keywords

β-Catenin DDP resistance GSK3β miR-425-5p prostate cancer (PCa) 

Notes

References

  1. Acebron SP, Karaulanov E, Berger BS, Huang YL and Niehrs C 2014 Mitotic Wnt signaling promotes protein stabilization and regulates cell size. Mol. Cell. 54 663–674CrossRefGoogle Scholar
  2. Ahmad I and Sansom OJ 2018 Role of Wnt signalling in advanced prostate cancer. J. Pathol. 245 3–5CrossRefGoogle Scholar
  3. Al-Eryani L, Jenkins SF, States VA, Pan J, Malone JC, Rai SN, Galandiuk S, Giri AK, et al. 2018 miRNA expression profiles of premalignant and malignant arsenic-induced skin lesions. PLoS One 13 e0202579 CrossRefGoogle Scholar
  4. Avci CB, Harman E, Dodurga Y, Susluer SY and Gunduz C 2013 Therapeutic potential of an anti-diabetic drug, metformin: Alteration of miRNA expression in prostate cancer cells. Asian Pac. J. Cancer Prev. 14 765–768CrossRefGoogle Scholar
  5. Cristobal I, Madoz-Gurpide J, Rojo F and Garcia-Foncillas J 2016 Potential therapeutic value of miR-425-5p in metastatic colorectal cancer. J. Cell Mol. Med. 20 2213–2214CrossRefGoogle Scholar
  6. Damodaran S, Kyriakopoulos CE and Jarrard DF 2017 Newly diagnosed metastatic prostate cancer: Has the paradigm changed? Urol. Clin. North Am. 44 611–621CrossRefGoogle Scholar
  7. Dell’Atti L 2015 The role of the digital rectal examination as diagnostic test for prostate cancer detection in obese patients. J. BUON. 20 1601–1605PubMedGoogle Scholar
  8. Druskin SC, Tosoian JJ, Young A, Collica S, Srivastava A, Ghabili K, Macura KJ, Carter HB, et al. 2018 Combining prostate health index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer. BJU Int. 121 619–626CrossRefGoogle Scholar
  9. Felgueiras J, Silva JV and Fardilha M 2014 Prostate cancer: The need for biomarkers and new therapeutic targets. J. Zhejiang Univ., Sci., B 15 16–42CrossRefGoogle Scholar
  10. Filella X and Foj L 2017 miRNAs as novel biomarkers in the management of prostate cancer. Clin. Chem. Lab. Med. 55 715–736CrossRefGoogle Scholar
  11. Folini M, Gandellini P, Longoni N, Profumo V, Callari M, Pennati M, Colecchia M, Supino R, et al. 2010 miR-21: An oncomir on strike in prostate cancer. Mol. Cancer 9 12CrossRefGoogle Scholar
  12. Gasparian ME, Bychkov ML, Yagolovich AV, Kirpichnikov MP and Dolgikh DA 2017 The effect of cisplatin on cytotoxicity of anticancer cytokine TRAIL and its receptor-selective mutant variant DR5-B(1). Dokl. Biochem. Biophys. 477 385–388CrossRefGoogle Scholar
  13. Genovese I, Ilari A, Assaraf YG, Fazi F and Colotti G 2017 Not only P-glycoprotein: Amplification of the abcb1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins. Drug Resist. Updates 32 23–46CrossRefGoogle Scholar
  14. Geretto M, Pulliero A, Rosano C, Zhabayeva D, Bersimbaev R and Izzotti A 2017 Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators. Am. J. Cancer Res. 7 1350–1371PubMedPubMedCentralGoogle Scholar
  15. Henrique R, Oliveira AI, Costa VL, Baptista T, Martins AT, Morais A, Oliveira J and Jerónimo C 2013 Epigenetic regulation of mdr1 gene through post-translational histone modifications in prostate cancer. BMC Genomics 14 898CrossRefGoogle Scholar
  16. Houede N, Piazza PV and Pourquier P 2018 LINE-1 as a therapeutic target for castration-resistant prostate cancer. Front. Biosci. (Landmark Ed) 23 1292–1309CrossRefGoogle Scholar
  17. Kimura Y, Morita SY, Matsuo M and Ueda K 2007 Mechanism of multidrug recognition by mdr1/abcb1. Cancer Sci. 98 1303–1310CrossRefGoogle Scholar
  18. Lage H 2016 Gene therapeutic approaches to overcome abcb1-mediated drug resistance. Recent Results Cancer Res. 209 87–94CrossRefGoogle Scholar
  19. Li Y, Ahmed F, Ali S, Philip PA, Kucuk O and Sarkar FH 2005 Inactivation of nuclear factor kappab by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res. 65 6934–6942CrossRefGoogle Scholar
  20. Li Z, Meng Q, Pan A, Wu X, Cui J, Wang Y and Li L 2017 MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24. Oncotarget 8 19455–19466PubMedGoogle Scholar
  21. Litwin MS and Tan HJ 2017 The diagnosis and treatment of prostate cancer: A review. J. Am. Med. Assoc. 317 2532–2542CrossRefGoogle Scholar
  22. Munoz M, Henderson M, Haber M and Norris M 2007 Role of the mrp1/abcc1 multidrug transporter protein in cancer. IUBMB Life 59 752–757CrossRefGoogle Scholar
  23. Munoz-Moreno L, Arenas MI, Schally AV, Fernandez-Martinez AB, Zarka E, Gonzalez-Santander M, Carmena MJ, Vacas E, et al. 2013 Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer. Int. J. Cancer 132 755–765CrossRefGoogle Scholar
  24. Murillo-Garzon V and Kypta R 2017 WNT signalling in prostate cancer. Nat. Rev. Urol. 14 683–696CrossRefGoogle Scholar
  25. Pakula H, Xiang D and Li Z 2017 A tale of two signals: AR and WNT in development and tumorigenesis of prostate and mammary gland. Cancers (Basel) 9 Google Scholar
  26. Pathak RK, Basu U, Ahmad A, Sarkar S, Kumar A, Surnar B, Ansari S, Wilczek K, et al. 2018 A designer bow-tie combination therapeutic platform: An approach to resistant cancer treatment by simultaneous delivery of cytotoxic and anti-inflammatory agents and radiation. Biomaterials 187 117–129CrossRefGoogle Scholar
  27. Pennati M, Lopergolo A, Profumo V, De Cesare M, Sbarra S, Valdagni R, Zaffaroni N, Gandellini P, et al. 2014 miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells. Biochem. Pharmacol. 87 579–597CrossRefGoogle Scholar
  28. Polotti CF, Kim CJ, Chuchvara N, Polotti AB, Singer EA and Elsamra S 2017 Androgen deprivation therapy for the treatment of prostate cancer: A focus on pharmacokinetics. Expert Opin. Drug Metab. Toxicol. 13 1265–1273CrossRefGoogle Scholar
  29. Razdan A, de Souza P and Roberts TL 2018 Role of microRNAs in treatment response in prostate cancer. Curr. Cancer Drug Targets 18 929–944CrossRefGoogle Scholar
  30. Sánchez C, Mendoza P, Contreras HR, Vergara J, McCubrey JA, Huidobro C and Castellón EA 2009 Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs. Prostate 69 1448–1459CrossRefGoogle Scholar
  31. Saupe M, Rauschenberger L, Preuß M, Oswald S, Fussek S, Zimmermann U, Walther R, Knabbe C, et al. 2015 Differential expression of the multidrug resistance 1 (mdr1) protein in prostate cancer cells is independent from anticancer drug treatment and y box binding protein 1 (yb-1) activity. World J. Urol. 33 1481–1486CrossRefGoogle Scholar
  32. Shen FR, Yan CY, Liu M, Feng YH and Chen YG 2013 Relationship between multidrug resistance 1 polymorphisms and the risk of prostate cancer in Chinese populations. Genet. Mol. Res. 12 3806–3812CrossRefGoogle Scholar
  33. Su F, Ahn S, Saha A, DiGiovanni J and Kolonin MG 2018 Adipose stromal cell targeting suppresses prostate cancer epithelial-mesenchymal transition and chemoresistance. Oncogene  https://doi.org/10.1038/s41388-018-0558-8. [Epub ahead of print]CrossRefGoogle Scholar
  34. Sullivan GF, Amenta PS, Villanueva JD, Alvarez CJ, Yang JM and Hait WN 1998 The expression of drug resistance gene products during the progression of human prostate cancer. Clin. Cancer Res. 4 1393–1403PubMedGoogle Scholar
  35. Sun L, Jiang R, Li J, Wang B, Ma C, Lv Y and Mu N 2017 MicroRNA-425-5p is a potential prognostic biomarker for cervical cancer. Ann. Clin. Biochem. 54 127–133CrossRefGoogle Scholar
  36. Valkenburg KC, Yu X, De Marzo AM, Spiering TJ, Matusik RJ and Williams BO 2014 Activation of Wnt/beta-catenin signaling in a subpopulation of murine prostate luminal epithelial cells induces high grade prostate intraepithelial neoplasia. Prostate 74 1506–1520CrossRefGoogle Scholar
  37. Verdoodt B, Neid M, Vogt M, Kuhn V, Liffers ST, Palisaar RJ, Noldus J, Tannapfel A, et al. 2013 MicroRNA-205, a novel regulator of the anti-apoptotic protein Bcl2, is downregulated in prostate cancer. Int. J. Oncol. 43 307–314CrossRefGoogle Scholar
  38. Wang L, Dehm SM, Hillman DW, Sicotte H, Tan W, Gormley M, Bhargava V, Jimenez R, et al. 2018 A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone. Ann. Oncol. 29 352–360.CrossRefGoogle Scholar
  39. Yan B, Guo Q, Nan XX, Wang Z, Yin Z, Yi L, Wei YB, Gao YL, et al. 2015 Micro-ribonucleic acid 29b inhibits cell proliferation and invasion and enhances cell apoptosis and chemotherapy effects of cisplatin via targeting of DNMT3b and AKT3 in prostate cancer. OncoTargets Ther. 8 557–565Google Scholar
  40. Yang CH, Pfeffer SR, Sims M, Yue J, Wang Y, Linga VG, Paulus E, Davidoff AM, et al. 2015 The oncogenic microRNA-21 inhibits the tumor suppressive activity of FBXO11 to promote tumorigenesis. J. Biol. Chem. 290 6037–6046CrossRefGoogle Scholar
  41. Zhang Z, Li Y, Fan L, Zhao Q, Tan B, Li Z and Zang A 2015 microRNA-425-5p is upregulated in human gastric cancer and contributes to invasion and metastasis in vitro and in vivo. Exp. Ther. Med. 9 1617–1622CrossRefGoogle Scholar
  42. Zhang Y, Hu X, Miao X, Zhu K, Cui S, Meng Q, Sun J and Wang T 2016 MicroRNA-425-5p regulates chemoresistance in colorectal cancer cells via regulation of programmed cell death 10. J. Cell Mol. Med. 20 360–369CrossRefGoogle Scholar
  43. Zhang Z, Wen M, Guo J, Shi J, Wang Z, Tan B, Zhang G, Zheng X, et al. 2017 Clinical value of miR-425-5p detection and its association with cell proliferation and apoptosis of gastric cancer. Pathol., Res., Pract. 213 929–937Google Scholar
  44. Zhu M, Huang Z, Zhu D, Zhou X, Shan X, Qi LW, Wu L, Cheng W, et al. 2017 A panel of microRNA signature in serum for colorectal cancer diagnosis. Oncotarget 8 17081–17091PubMedPubMedCentralGoogle Scholar
  45. Zhu W, Ma Y, Zhuang X and Jin X 2018 MicroRNA-425 is downregulated in nasopharyngeal carcinoma and regulates tumor cell viability and invasion by targeting hepatoma-derived growth factor. Oncol. Lett. 15 6345–6351PubMedPubMedCentralGoogle Scholar

Copyright information

© Indian Academy of Sciences 2019

Authors and Affiliations

  1. 1.Department of UrologyChongqing Three Gorges Central HospitalChongqingPeople’s Republic of China
  2. 2.Department of OncologyChongqing Three Gorges Central HospitalChongqingPeople’s Republic of China

Personalised recommendations